Johnson & Johnson
Johnson & Johnson
JNJ | NYSE · Health Care
About Johnson & Johnson (JNJ)
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
- CEO
- Joaquin Duato
- Employees
- 140.8K
- Headquarters
- United States
- Sector
- Health Care
- Industry
- PHARMACEUTICAL PREPARATIONS
- Exchange
- NYSE
- Token
- JNJ
- Chain
- Robinhood Chain
Stats
- Market cap
- $665B
- Revenue (TTM)
- $99.3B
- EPS (TTM)
- $6.60
- Price / earnings ratio
- 41.87x
- Debt / equity
- 0.55x
- Gross margin
- 68.12%
- Net margin
- 0.83%
- Current ratio
- 1.02x
- Next earnings
- Jan 26, 2027
- Yesterday's volume *
- 9.8M
- Avg. daily volume *
- 7.5M
- Open
- $272.41
- Previous close
- $266.17
- Today's range
- $267.67 – $277.35
- Yesterday's range *
- $267.67 – $277.35
- 52 week range
- $185.12 – $282.02
- Dividend yield
- 1.91%
* Derived from daily price history
Earnings
Johnson & Johnson reported earnings per share (EPS) of $2.59 on Oct 13 '26, beating estimates of $2.52 by 2.78%. Johnson & Johnson is expected to release its next earnings on Jan 26 '27, with an EPS estimate of $2.90.
Price targets
What analysts think JNJ stock price will be.
Stock rating
What analysts recommend for JNJ stock, on a scale from 1(buy) to 5(sell).
Based on 23 analysts
Johnson & Johnson Stock News
Zimmer Biomet Soars 15% as Hip and Tech Growth Lifts Guidance, “Validating the Progress” of Its Strategy
finance.yahoo.com ·
Plaintiffs Urge Conn. Appellate Court to Allow $25 Million Asbestos Talc Verdict
harrismartin.com ·
Anthropic's quarterly R&D passed Microsoft's
rdworldonline.com ·
How well is J&J’s incubator model working?
finance.yahoo.com ·
TREMFYA® (guselkumab) reimbursed for the treatment of moderately to severely active Crohn’s disease and ulcerative colitis for use in Ireland
imt.ie ·
PROTEUS: Perioperative Apalutamide Plus ADT Improves EFS in High-Risk Locally Advanced Prostate Cancer
endocrinologyadvisor.com ·
Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors.
finance.yahoo.com ·
All Ecosystem Coins
Coins paired with JNJ
Buying JNJ